Covington Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.83M | Sell |
28,559
-91
| -0.3% | -$13.1K | 0.17% | 136 |
|
|
2022
Q2 | $4.39M | Sell |
28,650
-648
| -2% | -$99K | 0.18% | 135 |
|
|
2022
Q1 | $4.75M | Buy |
29,298
+766
| +3% | +$111K | 0.17% | 135 |
|
|
2021
Q4 | $3.86M | Buy |
28,532
+1,404
| +5% | +$166K | 0.13% | 149 |
|
|
2021
Q3 | $2.93M | Sell |
27,128
-205
| -0.8% | -$23.4K | 0.11% | 163 |
|
|
2021
Q2 | $3.08M | Sell |
27,333
-391
| -1% | -$44K | 0.12% | 157 |
|
|
2021
Q1 | $3M | Sell |
27,724
-416
| -1% | -$44.5K | 0.13% | 149 |
|
|
2020
Q4 | $3.02M | Sell |
28,140
-588
| -2% | -$56.5K | 0.14% | 142 |
|
|
2020
Q3 | $2.52M | Sell |
28,728
-1,086
| -4% | -$102K | 0.12% | 147 |
|
|
2020
Q2 | $2.93M | Sell |
29,814
-199
| -0.7% | -$17.5K | 0.16% | 135 |
|
|
2020
Q1 | $2.29M | Buy |
30,013
+2,825
| +10% | +$241K | 0.15% | 132 |
|
|
2019
Q4 | $2.41M | Sell |
27,188
-759
| -3% | -$63K | 0.13% | 138 |
|
|
2019
Q3 | $2.12M | Buy |
27,947
+1,219
| +5% | +$83.6K | 0.12% | 139 |
|
|
2019
Q2 | $1.94M | Buy |
26,728
+485
| +2% | +$38.1K | 0.12% | 141 |
|
|
2019
Q1 | $2.12M | Sell |
26,243
-3,917
| -13% | -$320K | 0.13% | 133 |
|
|
2018
Q4 | $2.78M | Sell |
30,160
-11,189
| -27% | -$984K | 0.19% | 114 |
|
|
2018
Q3 | $3.91M | Sell |
41,349
-2,000
| -5% | -$190K | 0.24% | 105 |
|
|
2018
Q2 | $4.02M | Sell |
43,349
-10,950
| -20% | -$1.07M | 0.26% | 100 |
|
|
2018
Q1 | $5.14M | Sell |
54,299
-1,219
| -2% | -$134K | 0.34% | 87 |
|
|
2017
Q4 | $5.37M | Buy |
55,518
+449
| +0.8% | +$42.3K | 0.33% | 87 |
|
|
2017
Q3 | $4.89M | Sell |
55,069
-417
| -0.8% | -$31.7K | 0.32% | 90 |
|
|
2017
Q2 | $4.02M | Sell |
55,486
-243
| -0.4% | -$16.3K | 0.33% | 95 |
|
|
2017
Q1 | $3.63M | Sell |
55,729
-1,939
| -3% | -$122K | 0.31% | 95 |
|
|
2016
Q4 | $3.61M | Sell |
57,668
-161
| -0.3% | -$9.83K | 0.32% | 94 |
|
|
2016
Q3 | $3.65M | Buy |
57,829
+200
| +0.3% | +$12.9K | 0.33% | 90 |
|
|
2016
Q2 | $3.57M | Sell |
57,629
-367
| -0.6% | -$22.4K | 0.33% | 93 |
|
|
2016
Q1 | $3.31M | Sell |
57,996
-94
| -0.2% | -$5.24K | 0.32% | 97 |
|
|
2015
Q4 | $3.44M | Sell |
58,090
-439
| -0.8% | -$25.3K | 0.34% | 94 |
|
|
2015
Q3 | $3.19M | Sell |
58,529
-1,390
| -2% | -$90.5K | 0.33% | 97 |
|
|
2015
Q2 | $4.03M | Sell |
59,919
-23,331
| -28% | -$1.52M | 0.36% | 90 |
|
|
2015
Q1 | $4.87M | Sell |
83,250
-547
| -0.7% | -$33K | 0.47% | 74 |
|
|
2014
Q4 | $5.48M | Sell |
83,797
-1,576
| -2% | -$99.4K | 0.49% | 74 |
|
|
2014
Q3 | $4.93M | Buy |
85,373
+360
| +0.4% | +$20K | 0.45% | 77 |
|
|
2014
Q2 | $4.95M | Sell |
85,013
-13,201
| -13% | -$693K | 0.45% | 76 |
|
|
2014
Q1 | $5.05M | Sell |
98,214
-10,667
| -10% | -$539K | 0.49% | 71 |
|
|
2013
Q4 | $5.75M | Sell |
108,881
-468
| -0.4% | -$23K | 0.58% | 63 |
|
|
2013
Q3 | $4.89M | Sell |
109,349
-3,279
| -3% | -$145K | 0.56% | 66 |
|
|
2013
Q2 | $4.66M | Buy |
+112,628
| New | +$4.93M | 0.57% | 63 |
|
Other funds holding ABBV
Covington Capital Management's ABBV Position: Q3 2022 in Review
Covington Capital Management reduced its AbbVie (ABBV) stake by 0.32% in Q3 2022, selling an estimated $13.1K and leaving 28,559 shares worth $3.83M. The position accounts for 0.17% of the portfolio, ranked #136.
Covington Capital Management first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $5.75M in Q4 2013. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Covington Capital Management held 28,559 shares of AbbVie worth $3.83M as of Q3 2022.
- Covington Capital Management sold 91 AbbVie shares in Q3 2022, an estimated $13.1K.
- AbbVie made up 0.17% of Covington Capital Management's portfolio in Q3 2022, its #136 holding.
- Covington Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Covington Capital Management's AbbVie position peaked at $5.75M in Q4 2013.
- 2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.